Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celvapan Dose Finding in Pediatric H1N1 Vaccination
NCT00976469Phase 2Completed
- Sponsor
- Resilience Government Services
- Start
- Sep 2009
- Primary completion
- Apr 2010
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of inactivated influenza vaccine (vero cell-derived) in influenza A H1N1 infection (H1N1) (2 arms), sponsored by Resilience Government Services. Primary endpoints: Immune response to H1N1 pandemic influenza vaccine at 42 days and Safety of H1N1 pandemic influenza vaccine. Started Sep 2009; status: completed.
02
Drugs
inactivated influenza vaccine (vero cell-derived)
03
Conditions
influenza A H1N1 infection (H1N1)
Beyond the preview
Go deeper on NCT00976469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00976469.